Navigation Links
Oncology is the Most Active Therapeutic Area for Phase II/III R&D
Date:11/21/2013

BURLINGTON, Mass., Nov. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while metabolic drugs account for one-quarter of drugs recently filed for approval or approved, oncology continues to be the most active therapeutic area for Phase II and III research and development (R&D). Among the top 25 biopharmaceutical companies, oncology is the focus for 30 percent of Phase II drugs and 22 percent of Phase III drugs. According to Decision Resources' Strategic Insights report entitled R&D Trends: Will Pharma's Investment Deliver?, other active therapeutic areas of R&D include obesity drugs, anti-diabetics, anti-infectives, central nervous system drugs, musculoskeletal/pain drugs and respiratory drugs.

The analysis also reveals that despite enduring multiple failures in 2011 and 2012 with drugs in Phase III development, Novartis is poised to benefit from a rich Phase III pipeline. Decision Resources expects Novartis will replace Pfizer as the top global biopharmaceutical company in 2015.

"To maximize R&D investments, biopharmaceutical companies must continue to address Phase II and III attrition and identify better prospects early on," said Decision Resources Group Senior Vice President Kate Hohenberg. "As more than half of the costs associated with new drugs are accrued from Phase II on, this could lead to significant cost savings."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013s Top Oncology Projects to Watch
2. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
3. In The Face Of Increasing Healthcare Spend And High-Cost Targeted Treatment, Market Access Barriers Continue To Rise For Targeted Oncology Drugs
4. Elekta Opens Global Education Center for Oncology and Neuroscience Professionals
5. Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials, new life science webinar hosted by Xtalks
6. Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
7. Oncology Therapeutics Market in India to 2018 Report
8. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
9. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
10. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
Breaking Biology News(10 mins):